Nascent Biotech completes payment of variable convertible note

Nascent Biotech has completed payment of all outstanding variable convertible debt obligations. On August 30, 2023, the Company and the Noteholder YA II PN, LLC agreed to terms that fully satisfy the Company’s outstanding obligation with respect to the related note. Under the terms of the agreement, the Noteholder did not charge any interest and the obligation is now considered “settled in full” with no conversion to common shares.